Phase 2 Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 40 and 80 years old (inclusive) at the time of screening
- You have been diagnosed with clinically established or clinically probable Parkinson's Disease
- Your Parkinson's Disease is linked to a specific gene called LRRK2, confirmed through a special genetic test used in this trial
- Your Parkinson's symptoms are in a mild to moderate range, based on a standard rating scale called the Modified Hoehn and Yahr scale (scores 1 to 2.5) (confirm with trial site)
Who may not be able to join:
- You have a form of parkinsonism that is caused by another condition or is considered an atypical type, rather than standard Parkinson's Disease
- You have diabetes that is not well controlled, shown by a blood sugar marker (HbA1c) above 8%
- You have other serious health conditions identified through your medical history, physical examination, or tests done at screening (confirm with trial site)
Please note: There are additional eligibility requirements outlined in the full study protocol that are not listed here. These may apply depending on which part of the trial you are being considered for.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Fatta B Nahab, MD, FAAN FANA, Neuron23 Inc.
Phone: 650-228-2527
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from baseline in the Roche digital biomarker score using the Roche Parkinson's Disease application (v3.0) compared to placebo; Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) compared to placebo
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.